Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
9.48
+0.15 (1.61%)
Apr 8, 2026, 10:09 AM EDT - Market open
Kyverna Therapeutics Employees
Kyverna Therapeutics had 130 employees as of December 31, 2025. The number of employees increased by 18 or 16.07% compared to the previous year.
Employees
130
Change (1Y)
18
Growth (1Y)
16.07%
Revenue / Employee
n/a
Profits / Employee
-$1,240,823
Market Cap
573.12M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 130 | 18 | 16.07% |
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Dec 31, 2023 | 96 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| ProKidney | 231 |
| CorMedix | 191 |
| Rigel Pharmaceuticals | 174 |
| Prime Medicine | 146 |
| Ocugen | 116 |
| Upstream Bio | 75 |
| Prothena Corporation | 67 |
KYTX News
- 12 days ago - Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - GlobeNewsWire
- 5 weeks ago - Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 6 weeks ago - Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer - GlobeNewsWire
- 3 months ago - Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 3 months ago - Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock - GlobeNewsWire